References
- BommareddyPKShettigarMKaufmanHLIntegrating oncolytic viruses in combination cancer immunotherapyNat Rev Immunol201818849851329743717
- ParatoKABreitbachCJLe BoeufFThe oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancersMol Ther201220474975822186794
- McCartJAWardJMLeeJSystemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genesCancer Res200161248751875711751395
- ZehHJDowns-CannerSMcCartJAFirst-in-man study of western reserve strain oncolytic vaccinia virus: safety, systemic spread, and antitumor activityMol Ther201523120221425292189
- Downs-CannerSGuoZSRavindranathanRPhase 1 study of intravenous oncolytic poxvirus (vvDD) in patients with advanced solid cancersMol Ther20162481492150127203445
- KowalskySJLiuZFeistMSuperagonist IL-15-armed oncolytic virus elicits potent antitumor immunity and therapy that are enhanced with PD-1 blockadeMol Ther201826102476248630064894
- LunXAlainTZempFJMyxoma virus virotherapy for glioma in immunocompetent animal models: optimizing administration routes and synergy with rapamycinCancer Res201070259860820068158
- LunXYangWAlainTMyxoma virus is a novel oncolytic virus with significant antitumor activity against experimental human gliomasCancer Res200565219982999016267023
- ThomasDLDotyRTosicVMyxoma virus combined with rapamycin treatment enhances adoptive T cell therapy for murine melanoma brain tumorsCancer Immunol Immunother201160101461147221656158
- ZempFJLunXMcKenzieBATreating brain tumor-initiating cells using a combination of myxoma virus and rapamycinNeuro Oncol201315790492023585629
- OgbomoHZempFJLunXMyxoma virus infection promotes NK lysis of malignant gliomas in vitro and in vivoPLoS One201386e6682523762498
- FranceMRThomasDLLiuJMcFaddenGMacNeillALRoyEJIntraventricular injection of myxoma virus results in transient expression of viral protein in mouse brain ependymal and subventricular cellsJ Gen Virol201192Pt 119519920861319
- PellegattaSPolianiPLCornoDNeurospheres enriched in cancer stem-like cells are highly effective in eliciting a dendritic cell-mediated immune response against malignant gliomasCancer Res20066621102471025217079441
- PellegattaSFinocchiaroGDendritic cell vaccines for cancer stem cellsMethods Mol Biol200956823324719582431
- TosicVThomasDLKranzDMMyxoma virus expressing a fusion protein of interleukin-15 (IL15) and IL15 receptor alpha has enhanced antitumor activityPLoS One2014910e10980125329832
- ChahroudiAChavanRKozyrNVaccinia virus tropism for primary hematolymphoid cells is determined by restricted expression of a unique virus receptorJ Virol20057916103971040716051832
- KoberCRohnSWeibelSGeissingerUChenNGSzalayAAMicroglia and astrocytes attenuate the replication of the oncolytic vaccinia virus LIVP 1.1.1 in murine GL261 gliomas by acting as vaccinia virus trapsJ Transl Med201513121626149494
- WokatschRVaccinia virusMajerMPlotkinSAStrains of Human VirusesBaselKerger1972241257 Available from: https://www.karger.com/Article/FullText/393659Accessed September 3, 2018
- LunXQJangJHTangNEfficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with rapamycin or cyclophosphamideClin Cancer Res20091582777278819351762
- MossmanKLeeSFBarryMBoshkovLMcFaddenGDisruption of M-T5, a novel myxoma virus gene member of poxvirus host range superfamily, results in dramatic attenuation of myxomatosis in infected European rabbitsJ Virol1996707439444108676463